Biocon Limited — Q4 FY25
Biocon delivered a strong Q4 FY25 with consolidated revenue of INR 4,417 crore, up 15% YoY on a like-for-like basis, driven by generics (+46% YoY) and biosimilars (+9% YoY).
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY25
Biosimilar Ustekinumab launch in February 2025
Yesintek (biosimilar to Stelara) will launch in the US in February 2025, with a global rollout including Europe.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY25
Generic liraglutide launch in UK in Q4 FY25 and EU in Q1 FY26
First GLP-1 generic will launch in the UK in Q4 FY25, followed by EU national launches in Q1 FY26.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY25
Biosimilar Bevacizumab and Aspart US approvals pending site clearance
With VAI status for manufacturing sites, management expects expedited FDA review for these biosimilars.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1